Search
Perspective Therapeutics Inc
CATXAdd to Watchlist
2.950USD
-0.025-0.84%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
336.44MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Perspective Therapeutics Inc is 8.14, ranking 161 out of 389 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 20.00 and a low of 5.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
12.385
Target Price
+315.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Perspective Therapeutics Inc
CATX
14
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Perspective Therapeutics Inc's expected revenue for the next quarter?
Perspective Therapeutics Inc's expected revenue is 89.18K.
What is Perspective Therapeutics Inc's price target?
Analysts forecast that Perspective Therapeutics Inc's price target is USD 12.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 5.00.
How have Perspective Therapeutics IncCATX's recent earnings per share performed?
The market expectation was USD -0.25, while Perspective Therapeutics IncCATX's earnings per share (EPS) for the previous quarter was USD -0.50. EPS for the next quarter is expected at USD -0.25.
What is the analyst rating for Perspective Therapeutics Inc?
Based on the ratings of Perspective Therapeutics Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
